Goodwin's Capital Markets Team is one of the most innovative and active in the world. Our team of sophisticated capital markets lawyers have extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.
With more than 100 lawyers located in major financial centers, we advise investment banks, issuers, and institutional investors on the full range of capital market transactions. Our team has extensive experience handling cross-border transactions, including those involving the United States, Europe, China, Canada, Australia, and Israel.
| Company Name | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
| Rapport Therapeutics (NASDAQ: RAPP) | Goldman Sachs Jefferies TD Securities Stifel | 06/06/2024 S-1 | $17.00 | $136 million | $16 – $18 |
| Silvaco Group, Inc. (NASDAQ: SVCO) | Jefferies TD Securities Craig-Hallum Capital Group Needham & Co. Rosenblatt Securities | 05/08/2024 S-1 | $19.00 | $114 million | $17 – $19 |
| Rubrik, Inc. (NASDAQ: RBRK) | Goldman Sachs Barclays Capital Citigroup Global Markets Wells Fargo Securities Guggenheim | 04/24/2024 S-1 | $32.00 | $752 million | $28 – $31 |
| PACS Group, Inc. (NASDAQ: PACS) | Citigroup Global Markets J.P. Morgan Securities Truist Securities RBC Capital Markets | 04/10/2024 S-1 | $21.00 | $450 million | $20 – $22 |
| Contineum Therapeutics (NASDAQ: CTNM) | Goldman Sachs Morgan Stanley RBC Capital Markets Stifel | 04/04/2024 S-1 | $16.00 | $110 million | $16 – $18 |
| Boundless Bio (NASDAQ: BOLD) | Goldman Sachs Goldman Sachs Leerink Piper Sandler Guggenheim | 03/27/2024 S-1 | $16.00 | $100 million | $15 – $17 |
| Metagenomi (NASDAQ: MGX) | J.P. Morgan BMO Chardan Cowen & Co. Jefferies Wells Fargo Securities | 02/08/2024 S-1 | $15.00 | $93.75 million | $15 – $17 |
| Kyverna Therapeutics (NASDAQ: KYTX) | J.P. Morgan Mogan Stanley Leerink Wells Fargo Securities | 02/07/2024 S-1 | $22.00 | $319 million | $20 – $21 |
| Fractyl Health (NASDAQ: GUTS) | BofA Securities Morgan Stanley Evercore | 02/01/2024 S-1 | $15.00 | $110 million | $14 – $16 |
| NYSE Neuroscience, Inc. (NASDAQ: ANRO) | Jefferies Cowen & Co. Stifel William Blair & Co. | 02/01/2024 S-1 | $16.00 | $128.64 million | $14 – $16 |
| ArriVent BioPharma, Inc. (NASDAQ: AVBP) | Goldman Sachs Jefferies Citigroup Global LifeSci Capital | 01/25/2024 S-1 | $18.00 | $175 million | $17 – $19 |
| CG Oncology (NASDAQ: CGON) | Morgan Stanley Cantor Fitzgerald Goldman Sachs LifeSci Capital | 01/24/2024 S-1 | $19.00 | $380 million | $16 – $18 |
| Company Name | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
| CARGO Therapeutics (NASDAQ: CRGX) | JPM Securities Jefferies Cowen & Co. Truist Securities | 11/09/2023 S-1 | $15.00 | $281.25 million | $15 – $17 |
| Lexeo Therapeutics (NASDAQ: LXEO) | JPM Securities Leerink Stifel RBC Capital Markets | 11/02/2023 S-1 | $11.00 | $100 million | $13 – $15 |
| Abivax SA (NASDAQ: ABVX) | Morgan Stanley Leerink LifeSci Capital RBC Capital Markets | 10/19/2023 S-1 | $11.60 | $216.91 million | $11.60 – $13 |
| Adlai Nortye Ltd. (NASDAQ: ANL) | Cantor Fitzgerald | 09/28/2023 F-1 | $23.00 | $57.5 million | $23 – $23 |
| Klaviyo, Inc. (NASDAQ: KVYO) | Goldman Sachs Morgan Stanley Citigroup Global Markets Barclays Capital | 09/19/2023 S-1 | $30.00 | $576 million | $27 – $29 |
| Neumora Therapeutics (NASDAQ: NMRA) | JPM Securities BofA Securities Stifel Guggenheim RBC Capital Markets William Blair & Co. | 09/14/2023 S-1 | $17.00 | $250.7 million | $16 – $18 |
| RayzeBio, Inc. (NASDAQ: RYZB) | JPM Securities Jefferies Evercore Group Truist Securities | 09/14/2023 S-1 | $18.00 | $311 million | $16 – $18 |
| Arm Holdings plc (NASDAQ: ARM) | Barclays Goldman Sachs J.P. Morgan Securities Mizuho Securities | 09/13/2023 F-1 | $51.00 | $4.8 billion | $47 – $51 |
| Turnstone Biologics (NASDAQ: TSBX) | BofA Securities Piper Sandler Leerink Partners | 07/20/2023 S-1 | $12.00 | $80 million | $12 – $14 |
| Sagimet Biosciences Inc. (NASDAQ: SGMT) | Goldman Sachs Cowen & Co. Piper Sandler JPM Securities | 07/13/2023 S-1 | $16.00 | $85 million | $15 – $17 |
| Apogee Therapeutics, Inc. (NASDAQ: APGE) | Jefferies Cowen & Co. Stifel Guggenheim Wedbush Securities | 07/13/2023 S-1 | $17.00 | $300.5 million | $15 – $17 |
| ACELYRIN, INC. (NASDAQ: SLRN) | Morgan Stanley Jefferies Cowen & Co. Piper Sandler | 05/04/2023 S-1 | $18.00 | $540 million | $16 – $18 |
| Mineralys Therapeutics, Inc. (NASDAQ: MLYS) | BofA Securities Evercore Stifel Guggenheim Credit Suisse Wells Fargo | 02/09/2023 S-1 | $16.00 | $192 million | $14 – $16 |
| Structure Therapeutics Inc. (NASDAQ: GPCR) | Jefferies SVB Securities Guggenheim BMO Capital Markets | 02/02/2023 S-1 | $15.00 | $161.1 million | $13 – $15 |
| Company Name | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
| Acrivon Therapeutics (NASDAQ: ACRV) | Jefferies Cowen & Co. Piper Sandler | 11/14/2022 S-1 | $12.50 | $94.38 million | $16 – $18 |
| Mobileye Global Inc. (NASDAQ: MBLY) | Goldman Sachs Morgan Stanley | 10/25/2022 S-1 | $21.00 | $861 million | $18 – $20 |
| Prime Medicine (NASDAQ: PRME) | JPMorgan Goldman Sachs Jefferies Morgan Stanley | 10/19/2022 S-1 | $17.00 | $175 million | $16 – $18 |
| Third Harmonic Bio (NASDAQ: THRD) | Morgan Stanley Jefferies Cowen & Co. LifeSci Capital | 09/14/2022 S-1 | $17.00 | $185.3 million | $16 – $18 |
| PepGen Inc. (NASDAQ: PEPG) | BofA Securities Stifel SVB Securities Wedbush Securities | 05/05/2022 S-1 | $12.00 | $108 million | $13 – $15 |
| Bausch + Lomb Corporation (NASDAQ: BLCO) | Morgan Stanley Goldman Sachs Citigroup J.P. Morgan Securities | 05/05/2022 S-1 | $18.00 | $630 million | $12 – $24 |
| HilleVax, Inc. (NASDAQ: HLVX) | J.P. Morgan Securities SVB Leerink Stifel Guggenheim | 04/28/2022 | $17.00 | $200 million | $16 – $18 |
| AN2 Therapeutics (NASDAQ: ANTX) | Oppenheimer & Co. Cowen & Co. SVB Leerink Evercore | 03/24/2022 S-1 | $15.00 | $69 million | $14 – $16 |
| Arcellx, Inc. (NASDAQ: ACLX) | Barclays Capital BofA Securities SVB Leerink William Blair & Co. | 02/04/2022 S-1 | $15.00 | $142.31 million | $15 – $17 |
| Vigil Neuro (NASDAQ: VIGL) | Morgan Stanley Jefferies Stifel Guggenheim | 01/11/2022 S-1 | $14.00 | $98 million | $14 – $16 |
| Credo Technology Group Holding Ltd (NASDAQ: CRDO) | Goldman Sachs BofA Securities Cowen & Co. Mizuho Securities | 01/26/2022 S-1 | $10.00 | $200 million | $10 – $12 |
| Amylyx Pharmaceuticals (NASDAQ: AMLX) | Evercore Goldman Sachs H.C. Wainwright SVB Leerink | 01/07/2022 S-1 | $19.00 | $190 million | $18 – $20 |
| Cincor Pharma (NASDAQ: CINC) | Evercore Jefferies Morgan Stanley Oppenheimer | 01/06/2022 S-1 | $17.00 | $193.60 million | $15 – $17 |
| Company Name | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
| Vaxxinity (NASDAQ: VAXX) | BofA Securities Evercore Jefferies | 11/11/2021 S-1 | $13.00 | $78 million | $14 – $16 |
| IO Biotech (NASDAQ: IOBT) | Cowen & Co. Jefferies Kempen & Co. Morgan Stanley & Co. | 11/04/2021 S-1 | $14.00 | $115.11 million | $14 – $17 |
| LianBio (NASDAQ: LIAN) | BofA Securities Goldman Sachs Jefferies Raymond James & Assoc. | 11/01/2021 S-1 | $16.00 | $325 million | $15 – $17 |
| Aura Biosciences (NASDAQ: AURA) | BTIG Cowen & Co. Evercore SVB Leerink | 10/29/2021 S-1 | $14.00 | $75.60 million | $14 – $16 |
| Xilio Therapeutics (NASDAQ: XLO) | Cowen & Co. Guggenheim Morgan Stanley & Co. Raymond James & Assoc. | 10/22/2021 S-1 | $16.00 | S117.65 million | $16 – $18 |
| Ventyx Biosciences, Inc. (NASDAQ: VTYX) | Evercore Jefferies LifeSci Capital Piper Sandle | 10/20/2021 S-1 | $16.00 | $174.30 million | $15 – $17 |
| Pyxis Oncology (NASDAQ: PYXS) | BofA Securities Credit Suisse Jefferies LifeSci Capital William Blair & Co. | 10/07/2021 S-1 | $16.00 | $168 million | $14 – $16 |
| Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) | SVB Leerink Cantor Fitzgerald Jefferies Wedbush Securities | 10/06/2021 S-1 | $16.00 | $160 million | $14 – $16 |
| DICE Therapeutics (NASDAQ: DICE) | SVB Leerink Evercore BofA Securities | 09/14/2021 S-1 | $17.00 | $204 million | $15 – $17 |
| Eliem Therapeutics (NASDAQ: ELYM) | SVB Leerink Evercore Stifel Nicolaus Guggenheim | 08/09/2021 S-1 | $12.50 | $92 million | $17 – $19 |
| Adagio Therapeutics (NASDAQ: ADGI) | Morgan Stanley Jefferies Stifel Nicolaus Guggenheim | 08/05/2021 S-1 | $17.00 | $355.8 million | $16 – $18 |
| Rani Therapeutics (NASDAQ: RANI) | BofA Securities Stifel Nicolaus Cantor Fitzgerald Canaccord Genuity | 07/30/2021 S-1 | $11.00 | $73.3 million | $14 – $16 |
| Immuneering (NASDAQ: IMRX) | Morgan Stanley Jefferies Cowen & Co. Guggenheim | 07/30/2021 S-1 | $15.00 | $129.4 million | $14 – $16 |
| Omega Therapeutics (NASDAQ: OMGA) | Goldman Sachs Jefferies Piper Sandler | 07/30/2021 S-1 | $17.00 | $125.8 million | $16 – $18 |
| Tenaya Therapeutics (NASDAQ: TNYA) | Morgan Stanley Cowen & Co. Piper Sandler | 07/30/2021 S-1 | $15.00 | $207 million | $14 – $16 |
| Nuvalent (NASDAQ: NUVL) | Jefferies SVB Securities Guggenheim BMO Capital Markets | 07/28/2021 S-1 | $17.00 | $190.6 million | $16 – $18 |
| Icosavax (NASDAQ: ICVX) | Jefferies Cowen Evercore William Blair | 07/28/2021 S-1 | $15.00 | $209.3 million | $14 – $16 |
| Rallybio (NASDAQ: RLYB) | Jefferies Cowen Evercore | 07/28/2021 S-1 | $13.00 | $92.7 million | $13 – $15 |
| Candel Therapeutics (NASDAQ: CADL) | Jefferies Credit Suisse BMO Capital Markets UBS | 07/26/2021 S-1 | $8.00 | $72 million | $13 – $15 |
| Caribou Biosciences (NASDAQ: CRBU) | BofA Securities Citigroup SVB Leerink | 07/22/2021 S-1 | $16.00 | $304 million | $14 – $16 |
| HCW Biologics (NASDAQ: HCWB) | Jefferies SVB Securities Guggenheim BMO Capital Markets | 07/19/2021 S-1 | $8.00 | $56 million | $8 – $10 |
| Imago BioSciences (NASDAQ: IMGO) | Jefferies Cowen & Co. Stifel Nicolaus Guggenheim | 07/15/2021 S-1 | $16.00 | $134.4 million | $14 – $16 |
| TScan Therapeutics (NASDAQ: TCRX) | Morgan Stanley Jefferies Cowen & Co. Barclays Capital | 07/15/2021 S-1 | $15.00 | $100 million | $15 – $17 |
| Erasca (NASDAQ: ERAS) | J.P. Morgan Morgan Stanley BofA Securities Evercore Guggenheim | 07/15/2021 S-1 | $16.00 | $345 million | $14 – $16 |
| Acumen Pharmaceuticals (NASDAQ: ABOS) | BofA Securities Credit Suisse Stifel Nicolaus UBS | 06/30/2021 S-1 | $16.00 | $160 million | $14 – $16 |
| Aerovate Therapeutics (NASDAQ: AVTE) | Jefferies Cowen & Co. Evercore Wedbush PacGrow | 06/29/2021 S-1 | $14.00 | $139.8 million | $13 – $15 |
| GH Research (NASDAQ: GHRS) | Cowen & Co. Stifel Nicolaus Canaccord Genuity JMP Securities | 06/24/2021 F-1 | $16.00 | $160 million | $14 – $16 |
| Graphite Bio (NASDAQ: GRPH) | Morgan Stanley BofA Securities Cowen & Co. SVB Leerink | 06/24/2021 S-1 | $17.00 | $273.7 million | $15 – $17 |
| Elevation Oncology (NASDAQ: ELEV) | J.P. Morgan Cowen & Co. SVB Leerink Wedbush PacGrow | 06/24/2021 S-1 | $16.00 | $100 million | $15 – $17 |
| Monte Rosa Therapeutics (NASDAQ: GLUE) | J.P. Morgan Cowen & Co. Piper Sandler Guggenheim | 06/23/2021 S-1 | $19.00 | $222.3 million | $17 – $19 |
| Ambrx Biopharma (NASDAQ: AMAM) | Goldman Sachs BofA Securities Cowen & Co. | 06/17/2021 S-1 | $18.00 | $126 million | $17 – $19 |
| atai Life Sciences (NASDAQ: ATAI) | Credit Suisse Citigroup Cowen & Co. Berenberg Capital Markets Cantor Fitzgerald RBC Capital Markets Canaccord Genuity | 06/17/2021 S-1 | $15.00 | $225 million | $13 – $15 |
| Cyteir Therapeutics (NASDAQ: CYT) | J.P. Morgan Morgan Stanley BofA Securities Wedbush PacGrow | 06/17/2021 S-1 | $18.00 | $133.3 million | $16 – $18 |
| Century Therapeutics (NASDAQ: IPSC) | J.P. Morgan BofA Securities SVB Leerink Piper Sandler | 06/17/2021 S-1 | $20.00 | $242.7 million | $18 – $20 |
| Lyell Immunopharma (NASDAQ: LYEL) | Goldman Sachs BofA Securities J.P. Morgan Morgan Stanley | 06/16/2021 S-1 | $17.00 | $425 million | $16 – $18 |
| Verve Therapeutics (NASDAQ: VERV) | J.P. Morgan Jefferies Guggenheim William Blair | 06/16/2021 S-1 | $19.00 | $306.7 million | $16 – $18 |
| Molecular Partners (NASDAQ: MOLN) | J.P. Morgan SVB Leerink Cowen & Co. RBC Capital Markets Kempen & Co. | 06/15/2021 S-1 | $21.25 | $63.8 million | $27.14 |
| Janux Therapeutics (NASDAQ: JANX) | BofA Securities Cowen & Co. Evercore H.C. Wainwright | 06/10/2021 S-1 | $17.00 | $222.9 million | $15 – $17 |
| Centessa Pharmaceuticals (NASDAQ: CNTA) | Morgan Stanley Goldman Sachs Jefferies Evercore | 05/27/2021 S-1 | $20.00 | $379.5 million | $18 – $20 |
| Day One Biopharmaceuticals (NASDAQ: DAWN) | J.P. Morgan Cowen & Co. Piper Sandler Wedbush PacGrow | 05/26/2021 S-1 | $16.00 | $184 million | $14 – $16 |
| Talaris Therapeutics (NASDAQ: TALS) | Morgan Stanley SVB Leerink Evercore Guggenheim | 05/06/2021 S-1 | $17.00 | $150 million | $16 – $18 |
| Valneva (NASDAQ: VALN) | Goldman Sachs Jefferies Guggenheim Bryan, Garnier & Co. | 05/06/2021 F-1 | $26.41 | $107.6 million | $24.04 – $28.85 |
| Werewolf Therapeutics (NASDAQ: HOWL) | Jefferies SVB Leerink Evercore H.C. Wainwright | 04/29/2021 S-1 | $16.00 | $120 million | $15 – $17 |
| Vaccitech (NASDAQ: VACC) | Morgan Stanley Jefferies Barclays William Blair H.C. Wainwright | 04/29/2021 S-1 | $17.00 | $110.5 million | $16 – $18 |
| Impel NeuroPharma (NASDAQ: IMPL) | Cowen & Co. Guggenheim Wedbush PacGrow | 04/22/2021 S-1 | $15.00 | $80 million | $14 – $16 |
| Rain Therapeutics (NASDAQ: RAIN) | Goldman Sachs Citigroup Piper Sandler Guggenheim | 04/22/2021 S-1 | $17.00 | $125 million | $16 – $18 |
| Biomea Fusion (NASDAQ: BMEA) | J.P. Morgan Jefferies Piper Sandler | 04/15/2021 S-1 | $17.00 | $153 million | $15 – $17 |
| Recursion Pharmaceuticals (NASDAQ: RXRX) | Goldman Sachs J.P. Morgan BofA Securities SVB Leerink Allen & Company KeyBanc Capital Markets | 04/15/2021 S-1 | $18.00 | $501.8 million | $16 – $18 |
| Reneo Pharmaceuticals (NASDAQ: RPHM) | Jefferies SVB Leerink Piper Sandler | 04/08/2021 S-1 | $15.00 | $93.8 million | $15 – $17 |
| VectivBio (NASDAQ: VECT) | BofA Securities SVB Leerink Credit Suisse LifeSci Capital | 04/08/2021 S-1 | $17.00 | $146.6 million | $16 – $18 |
| Achilles Therapeutics (NASDAQ: ACHL) | J.P. Morgan BofA Securities Piper Sandler Chardan Capital Markets Oppenheimer Kempen & Co | 03/30/2021 F-1 | $18.00 | $175.5 million | $17 – $19 |
| Design Therapeutics (NASDAQ: DSGN) | Goldman Sachs SVB Leerink Piper Sandler | 03/25/2021 S-1 | $20.00 | $276 million | $18 – $20 |
| Edgewise Therapeutics (NASDAQ: EWTX) | J.P. Morgan Goldman Sachs SVB Leerink | 03/25/2021 S-1 | $16.00 | $202.4 million | $14 – $16 |
| Ikena Oncology (NASDAQ: IKNA) | Jefferies Cowen & Co. Credit Suisse William Blair | 03/25/2021 S-1 | $16.00 | $143.8 million | $15 – $17 |
| LAVA Therapeutics (NASDAQ: LVTX) | J.P. Morgan Jefferies SVB Leerink | 03/24/2021 F-1 | $15.00 | $100.5 million | $14 – $16 |
| Connect Biopharma (NASDAQ: CNTB) | Jefferies SVB Leerink Piper Sandler China International Capital Corporation | 03/18/2021 F-1 | $17.00 | $219.9 million | $15 – $17 |
| Instil Bio (NASDAQ: TIL) | Morgan Stanley Jefferies Cowen & Co. | 03/18/2021 S-1 | $20.00 | $368 million | $17 – $19 |
| Finch Therapeutics (NASDAQ: FNCH) | BofA Securities Jefferies Evercore | 03/18/2021 S-1 | $17.00 | $127.5 million | $15 – $17 |
| Prometheus Biosciences (NASDAQ: RXDX) | SVB Leerink Credit Suisse Stifel Nicolaus Guggenheim | 03/11/2021 S-1 | $19.00 | $218.5 million | $16 – $18 |
| Longboard Pharmaceuticals (NASDAQ: LBPH) | Citigroup Evercore Guggenheim Cantor Fitzgerald | 03/11/2021 S-1 | $16.00 | $80 million | $14 – $16 |
| NexImmune (NASDAQ: NEXI) | Barclays Capital Cantor Fitzgerald Raymond James Allen & Company | 02/11/2021 S-1 | $17.00 | $126.5 million | $15 – $17 |
| Decibel Therapeutics (NASDAQ: DBTX) | Citigroup SVB Leerink BMO Capital Markets Barclays Capital | 02/11/2021 S-1 | $18.00 | $127 million | $16 – $18 |
| Adagene (NASDAQ: ADAG) | Goldman Sachs (Asia) Morgan Stanley Jefferies China Renaissance Securities (Hong Kong) | 02/08/2021 F-1 | $19.00 | $161 million | $17 – $19 |
| Vor Biopharma (NASDAQ: VOR) | Goldman Sachs Evercore Barclays Capital Stifel Nicolaus | 02/05/2021 S-1 | $18.00 | $203.4 million | $16 – $18 |
| Angion Biomedica (NASDAQ: ANGN) | Cowen & Co. Stifel Nicolaus H.C. Wainwright Oppenheimer | 02/04/2021 S-1 | $16.00 | $92 million | $14 – $16 |
| Bolt Biotherapeutics (NASDAQ: BOLT) | Morgan Stanley SVB Leerink Stifel Nicolaus Guggenheim | 02/04/2021 S-1 | $20.00 | $264.5 million | $16 – $18 |
| Immunocore (NASDAQ: IMCR) | Goldman Sachs J.P. Morgan Jefferies | 02/04/2021 F-1 | $26.00 | $297.1 million | $23 – $25 |
| Pharvaris (NASDAQ: PHVS) | Morgan Stanley BofA Securities Sunrise Securities Oppenheimer Kempen & Co | 02/04/2021 F-1 | $20.00 | $190.2 million | $17 – $19 |
| Terns Pharmaceuticals (NASDAQ: TERN) | J.P. Morgan Goldman Sachs Cowen & Co. | 02/04/2021 S-1 | $17.00 | $146.6 million | $15 – $17 |
| Sensei Biotherapeutics (NASDAQ: SNSE) | Citigroup Piper Sandler Berenberg Capital Markets Oppenheimer | 02/03/2021 S-1 | $19.00 | $152.6 million | $16 – $18 |
| Landos Biopharma (NASDAQ: LABP) | J.P. Morgan Jefferies SVB Leerink Raymond James | 02/03/2021 S-1 | $16.00 | $100 million | $15 – $17 |
| Sana Biotechnology (NASDAQ: SANA) | Morgan Stanley Goldman Sachs J.P. Morgan BofA Securities | 02/03/2021 S-1 | $25.00 | $675.6 million | $20 – $23 |
| Cullinan Management (NASDAQ: CGEM) | Morgan Stanley SVB Leerink Evercore H.C. Wainwright | 01/07/2021 S-1 | $21.00 | $287.4 million | $17 – $19 |
| Gracell Biotechnologies (NASDAQ: GRCL) | Citigroup Jefferies Piper Sandler Wells Fargo | 01/07/2021 F-1 | $19.00 | $209 million | $16 – $18 |
| Company Name | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
| BioAtla (NASDAQ: BCAB) | J.P. Morgan Jefferies Credit Suisse | 12/15/2020 S-1 | $18.00 | $217.4 million | $15 – $17 |
| AbCellera Biologics (NASDAQ: ABCL) | Credit Suisse Sifel Nicolaus Berenberg Capital Markets SVB Leerink BMO Capital Markets | 12/10/2020 S-1 | $20.00 | $555.5 million | $14 – $17 |
| 4D Molecular Therapeutics (NASDAQ: FDMT) | Goldman Sachs BofA Securities Evercore | 12/10/2020 S-1 | $23.00 | $222 million | $20 – $22 |
| Nanobiotix (NASDAQ: NBTX) | Jefferies Evercore UBS | 12/10/2020 F-1 | $11.14 | $100.4 million | $14.69 |
| Seer (NASDAQ: SEER) | J.P. Morgan Morgan Stanley BofA Securities Cowen & Co. | 12/03/2020 S-1 | $19.00 | $201.3 million | $16 – $18 |
| Sigilon Therapeutics (NASDAQ: SGTX) | Morgan Stanley Jefferies Barclays Capital Canaccord Genuity | 12/03/2020 S-1 | $18.00 | $144.9 million | $17 – $19 |
| Silverback Therapeutics (NASDAQ: SBTX) | Goldman Sachs SVB Leerink Stifel Nicolaus | 12/03/2020 S-1 | $21.00 | $277.7 million | $17 – $19 |
| Kinnate Biopharma (NASDAQ: KNTE) | Goldman Sachs SVB Leerink Piper Sandler | 12/02/2020 S-1 | $20.00 | $276 million | $16 – $18 |
| Maravai LifeSciences (NASDAQ: MRVI) | Morgan Stanley Jefferies Goldman Sachs | 11/19/2020 S-1 | $27.00 | $1.86 billion | $24 – $27 |
| Olema Pharmaceuticals (NASDAQ: OLMA) | J.P. Morgan Jefferies Cowen & Co. Canaccord Genuity | 11/18/2020 S-1 | $19.00 | $240.4 million | $16 – $18 |
| Atea Pharmaceuticals (NASDAQ: AVIR) | J.P. Morgan Morgan Stanley Evercore William Blair | 10/29/2020 S-1 | $24.00 | $345 million | $22 – $24 |
| SQZ Biotechnologies (NASDAQ: SQZ) | BofA Securities Evercore Stifel Nicolaus BTIG | 10/29/2020 S-1 | $16.00 | $81 million | $16 – $18 |
| Galecto (NASDAQ: GLTO) | BofA Securities SVB Leerink Credit Suisse | 10/28/2020 S-1 | $15.00 | $85 million | $14 – $16 |
| Foghorn Therapeutics (NASDAQ: FHTX) | Goldman Sachs Morgan Stanley Cowen & Co. | 10/22/2020 S-1 | $16.00 | $120 million | $15 – $17 |
| Abcam (NASDAQ: ABCM) | Morgan Stanley BofA Securities SVB Leerink Lazard Freres William Blair | 10/21/2020 F-1 | $17.50 | $180 million | $16.52 |
| Opthea (NASDAQ: OPT) | Citigroup SVB Leerink Oppenheimer Truist Securities | 10/16/2020 F-1 | $13.50 | $128.2 million | $17.26 |
| Aligos Therapeutics (NASDAQ: ALGS) | J.P. Morgan Jefferies Piper Sandler Cantor Fitzgerald | 10/15/2020 S-1 | $15.00 | $150 million | $15 – $16 |
| Praxis Precision Medicines (NASDAQ: PRAX) | Cowen & Co. Evercore Piper Sandler Wedbush PacGrow | 10/15/2020 S-1 | $19.00 | $218.5 million | $16 – $18 |
| Codiak Biosciences (NASDAQ: CDAK) | Goldman Sachs Evercore William Blair Wedbush PacGrow | 10/13/2020 S-1 | $15.00 | $82.5 million | $14 – $16 |
| Kronos Bio (NASDAQ: KRON) | Goldman Sachs Jefferies Cowen & Co. Piper Sandler | 10/08/2020 S-1 | $19.00 | $287.5 million | $16 – $18 |
| Shattuck Labs (NASDAQ: STTK) | Citigroup Cowen & Co. Evercore Needham | 10/08/2020 S-1 | $17.00 | $232.3 million | $14 – $16 |
| Spruce Biosciences (NASDAQ: SPRB) | Cowen & Co. SVB Leerink Credit Suisse RBC Capital Markets | 10/08/2020 S-1 | $15.00 | $103.5 million | $14 – $16 |
| Aziyo Biologics (NASDAQ: AZYO) | Piper Sandler Cowen & Co. Cantor Fitzgerald Truist Securities | 10/07/2020 S-1 | $17.00 | $50 million | $16 – $18 |
| C4 Therapeutics (NASDAQ: CCCC) | Jefferies Evercore BMO Capital Markets UBS | 10/01/2020 S-1 | $19.00 | $209.76 million | $16 – $18 |
| Immunome (NASDAQ: IMNM) | Ladenburg Thalmann Chardan Capital Markets | 10/01/2020 S-1 | $12.00 | $44.85 million | $11 – $13 |
| Oncorus (NASDAQ: ONCR) | Jefferies Evercore Piper Sandler | 10/01/2020 S-1 | $15.00 | $87 million | $14 – $16 |
| Orphazyme (NASDAQ: ORPH) | BofA Securities Cowen & Co. Guggenheim Danske Markets | 09/28/2020 F-1 | $11.00 | $50.17 million | $13.13 |
| Graybug Vision (NASDAQ: GRAY) | SVB Leerink Piper Sandler | 09/24/2020 S-1 | $16.00 | $90 million | $15 – $17 |
| PMV Pharmaceuticals (NASDAQ: PMVP) | Goldman Sachs BofA Securities Cowen & Co. Evercore | 09/24/2020 S-1 | $18.00 | $243.53 million | $16 – $18 |
| Prelude Therapeutics (NASDAQ: PRLD) | Morgan Stanley Goldman Sachs BofA Securities | 09/24/2020 S-1 | $19.00 | $181.90 million | $17 – $19 |
| Taysha Gene Therapies (NASDAQ: TSHA) | Goldman Sachs Morgan Stanley Jefferies | 09/23/2020 S-1 | $20.00 | $181 million | $18 – $20 |
| Athira Pharma (NASDAQ: ATHA) | Goldman Sachs Jefferies Stifel Nicolaus | 09/17/2020 S-1 | $17.00 | $204 million | $15 – $17 |
| COMPASS Pathways (NASDAQ: CMPS) | Cowen & Co. Evercore Berenberg Capital Markets | 09/17/2020 F-1 | $17.00 | $146.60 million | $14 – $16 |
| Dyne Therapeutics (NASDAQ: DYN) | J.P. Morgan Jefferies Piper Sandler Stifel Nicolaus | 09/16/2020 S-1 | $19.00 | $268 million | $16 – $18 |
| Metacrine (NASDAQ: MTCR) | Jefferies Evercore RBC Capital Markets Canaccord Genuity | 09/15/2020 S-1 | $13.00 | $85.02 million | $12 – $14 |
| Kymera Therapeutics (NASDAQ: KYMR) | Morgan Stanley BofA Securities Cowen & Co. Guggenheim | 08/20/2020 S-1 | $20.00 | $199.75 million | $16 – $18 |
| Harmony Biosciences (NASDAQ: HRMY) | Goldman Sachs Jefferies Piper Sandler | 08/18/2020 S-1 | $24.00 | $147.62 million | $20 – $23 |
| Inhibrx (NASDAQ: INBX) | Jefferies Evercore Credit Suisse | 08/18/2020 S-1 | $17.00 | $136.85 million | $16 – $18 |
| CureVac (NASDAQ: CVAC) | BofA Securities Jefferies Credit Suisse | 08/13/2020 F-1 | $16.00 | $245.33 million | $14 – $16 |
| Checkmate Pharmaceuticals (NASDAQ: CMPI) | BofA Securities Jefferies BMO Capital Markets | 08/06/2020 S-1 | $15.00 | $75 million | $14 – $16 |
| Freeline Therapeutics (NASDAQ: FRLN) | J.P. Morgan Morgan Stanley Evercore | 08/06/2020 F-1 | $18.00 | $158.82 million | $16 – $18 |
| Acutus Medical (NASDAQ: AFIB) | J.P. Morgan BofA Securities William Blair | 08/05/2020 S-1 | $18.00 | $182.64 million | $16 – $18 |
| Oak Street Health (NASDAQ: OSH) | J.P. Morgan Goldman Sachs Morgan Stanley | 08/05/2020 S-1 | $21.00 | $377.34 million | $15 – $17 |
| AlloVir (NASDAQ: ALVR) | Morgan Stanley J.P. Morgan SVB Leerink Piper Sandler | 07/29/2020 S-1 | $17.00 | $317.68 million | $16 – $18 |
| Annexon (NASDAQ: ANNX) | J.P. Morgan BofA Securities Cowen & Co. | 07/23/2020 S-1 | $17 | $288.36 million | $14 – $16 |
| Inozyme Pharma (NASDAQ: INZY) | BofA Securities Cowen & Co. Piper Sandler | 07/23/2020 S-1 | $16.00 | $128.8 million | $14 – $16 |
| iTeos Therapeutics (NASDAQ: ITOS) | J.P. Morgan SVB Leerink Piper Sandler | 07/23/2020 S-1 | $19.00 | $231.31 million | $16 – $18 |
| Nurix Therapeutics (NASDAQ: NRIX) | J.P. Morgan Piper Sandler Stifel Nicolaus | 07/23/2020 S-1 | $19.00 | $240.35 million | $16 – $18 |
| ALX Oncology (NASDAQ: ALXO) | Jefferies Credit Suisse Piper Sandler Cantor Fitzgerald | 07/16/2020 S-1 | $19.00 | $185.7 million | $15 – $17 |
| Berkeley Lights (NASDAQ: BLI) | J.P. Morgan Morgan Stanley Cowen & Co. | 07/16/2020 S-1 | $22.00 | $204.9 million | $16 – $18 |
| Pandion Therapeutics (NASDAQ: PAND) | Goldman Sachs Morgan Stanley SVB Leerink BMO Capital Markets | 07/16/2020 S-1 | $18.00 | $135 million | $16 – $18 |
| Renalytix AI (NASDAQ: RNLX) | J.P. Morgan Sitfel Nicolaus | 07/16/2020 F-1 | $13.50 | $85.1 million | $14.22 |
| Relay Therapeutics (NASDAQ: RLAY) | J.P. Morgan Goldman Sachs Cowen & Co. Guggenheim | 07/15/2020 S-1 | $20.00 | $460 million | $16 – $18 |
| Inventiva (NASDAQ: IVA) | Jefferies Stifel Nicolaus Guggenheim | 07/09/2020 F-1 | $14.40 | $123.8 million | $13.68 |
| NKarta (NASDAQ: NKTX) | Cowen & Co. Evercore Stifel Nicolaus Mizuho | 07/09/2020 S-1 | $18.00 | $289.8 million | $14 – $16 |
| Poseida Therapeutics (NASDAQ: PSTX) | BofA Securities Piper Sandler William Blair | 07/09/2020 S-1 | $16.00 | $257.6 million | $14 – $16 |
| Akouos, Inc. (NASDAQ: AKUS) | BofA Securities Cowen & Co. Piper Sandler | 06/25/2020 S-1 | $17.00 | $244.37 million | $14 – $16 |
| Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) | Jefferies SVB Leerink Credit Suisse | 06/25/2020 S-1 | $20.00 | $319.29 million | $16 – $18 |
| PolyPid Ltd. (NASDAQ: PYPD) | Barclays Capital BMO Capital Markets Raymond James | 06/25/2020 F-1 | $16.00 | $69.00 million | $15 – $17 |
| Progenity, Inc. (NASDAQ: PROG) | Piper Sandler Wells Fargo Securities | 06/19/2020 S-1 | $15.00 | $115 million | $14 – $16 |
| Repare Therapeutics Inc. (NASDAQ: RPTX) | Morgan Stanley Goldman Sachs Cowen & Co. Piper Sandler | 06/18/2020 S-1 | $20.00 | $253.00 million | $16 – $18 |
| Genetron Holdings Limited (NASDAQ: GTH) | Credit Suisse China International Capital Corporation | 06/18/2020 F-1 | $16.00 | $294.4 million | $11.50 – $13.50 |
| Royalty Pharma plc (NASDAQ: RPRX) | J.P. Morgan Morgan Stanley BofA Securities Goldman Sachs Citigroup UBS Securities | 06/15/2020 S-1 | $28.00 | $2.5 billion | $25 – $28 |
| Avidity Biosciences, Inc. (NASDAQ: RNA) | Cowen & Co. SVB Leerink Credit Suisse Wells Fargo Securities | 06/11/2020 S-1 | $18.00 | $298.08 million | $14 – $16 |
| Burning Rock Biotech Limited (NASDAQ: BNR) | Morgan Stanley BofA Securities Cowen & Co. | 06/11/2020 F-1 | $16.50 | $256.16 million | $13.50 – $15.50 |
| Generation Bio Co. (NASDAQ: GBIO) | J.P. Morgan Jefferies Cowen & Co. Wedbush Securities | 06/11/2020 S-1 | $19.00 | $229.99 million | $16 – $18 |
| Vaxcyte, Inc. (NASDAQ: PCVX) | BofA Securities Jefferies Evercore | 06/11/2020 S-1 | $16.00 | $287.50 million | $14 – $16 |
| Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) | Morgan Stanley Jefferies Cowen & Co. | 06/05/2020 S-1 | $17.00 | $244.37 million | $14 – $16 |
| Legend Biotech Corporation (NASDAQ: LEGN) | Morgan Stanley J.P. Morgan Jefferies | 06/05/2020 F-1 | $23.00 | $487.34 million | $18 – $20 |
| Applied Molecular Transport Inc. (NASDAQ: AMTI) | BofA Securities Jefferies SVB Leerink | 06/04/2020 S-1 | $14.00 | $177.10 million | $12 – $14 |
| Calliditas Therapeutics (NASDAQ: CALT) | Citigroup Jefferies Stifel Nicolaus | 06/04/2020 F-1 | $19.50 | $90.00 million | $19.77 |
| Pliant Therapeutics, Inc. (NASDAQ: PLRX) | Citigroup Cowen & Co. Piper Sandler | 06/02/2020 S-1 | $16.00 | $165.60 million | $14 – $16 |
| Inari Medical, Inc. (NASDAQ: NARI) | BofA Securities Morgan Stanley | 05/21/2020 S-1 | $19.00 | $179.22 million | $14 – $16 |
| ADC Therapeutics SA (NASDAQ: ADCT) | Morgan Stanley BofA Securities Cowen & Co. | 05/14/2020 F-1 | $19.00 | $267.56 million | $16 – $18 |
| Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) | Citigroup Jefferies | 05/07/2020 S-1 | $15.00 | $63.25 million | $14 – $16 |
| Lyra Therapeutics, Inc. (NASDAQ: LYRA) | BofA Securities Jefferies William Blair | 04/30/2020 S-1 | $16.00 | $64.40 million | $14 – $16 |
| ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) | J.P. Morgan Citigroup Jefferies Guggenheim | 04/23/2020 S-1 | $16.00 | $138 million | $14 – $16 |
| Keros Therapeutics, Inc. (NASDAQ: KROS) | Jefferies SVB Leerink Piper Sandler | 04/07/2020 S-1 | $16.00 | $110.40 million | $14 – $16 |
| Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) | Morgan Stanley Jefferies SVB Leerink Guggenheim | 04/02/2020 S-1 | $18.00 | $190.02 million | $16 – $18 |
| IMARA Inc. (NASDAQ: IMRA) | Morgan Stanley Citigroup SVB Leerink | 03/11/2020 S-1 | $16.00 | $86.48 million | $16 – $18 |
| Passage Bio, Inc. (NASDAQ: PASG) | J.P. Morgan Goldman Sachs Cowen & Co. | 02/27/2020 S-1 | $18.00 | $248.4 million | $16 – $18 |
| Revolution Medicines, Inc. (NASDAQ: RVMD) | J.P. Morgan Cowen & Co. SVB Leerink Guggenheim | 02/12/2020 S-1 | $17.00 | $273.7 million | $14 – $16 |
| Beam Therapeutics, Inc. (NASDAQ: BEAM) | J.P. Morgan Jefferies Barclays Capital | 02/05/2020 S-1 | $17.00 | $207 million | $15 – $17 |
| PPD, Inc. (NASDAQ: PPD) | Barclays Capital J.P. Morgan Morgan Stanley Goldman Sachs | 02/05/2020 S-1 | $27.00 | $1.80 billion | $24 – $27 |
| 1Life Healthcare (NASDAQ: ONEM) | J.P. Morgan Morgan Stanley | 01/30/2020 S-1 | $14.00 | $281 million | $14 – $16 |
| Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) | Goldman Sachs Cowen & Co. Guggenheim | 01/30/2020 S-1 | $17.00 | $183.28 million | $15 – $17 |
| Black Diamond Therapeutics (NASDAQ: BDTX) | J.P. Morgan Jefferies Cowen & Co. | 01/29/2020 S-1 | $19.00 | $231.3 million | $16 – $18 |
| I-Mab (NASDAQ: IMAB) | Jefferies China International Capital Corporation | 01/16/2020 F-1 | $14.00 | $119.25 million | $12 – $15 |